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Effective doseObjective: The use of alloxan as a diabetogenic agent at 150 mg/kg BW has been characterized by low
percentage induction and instability of the hyperglycemia induced. The present study examined its time
course effects with a view to suggesting the probable effective dose of the compound for animal studies.
Methods: Forty adult Wistar rats were equally randomized into two groups (I and II) and were injected
with single intraperitoneal dose of alloxan, 170 and 200 mg/kg BW respectively. Blood glucose concen-
tration (BGC) was monitored in consecutive phases of hourly for 3 h, 3 h interval for 15 h, 6 h interval
for 12 h and 9 h after. Changes with time in biomarkers of oxidative stress (SOD, CAT, GST and MDA)
and pancreas histopathology were studied.
Results: Alloxan at the evaluated doses produced a multiphasic blood glucose response. One hour post
alloxan injection, 90% of group I and 85% of group II animals exhibited diabetic hyperglycemia (glucose
level  200 mg/dL). Groups I and II respectively produced peak levels of hyperglycemia (586.8 and 575.9
mg/dL) at 9 and 12 h post alloxan administration. Hypoglycemia which is characteristic of experimental
diabetes was noted between the 15th and 21st hour in both groups (I and II) and resulted in 5 and 10%
mortality respectively. At 36th hour, hyperglycemia was restored and apparently sustained. Changes in
biomarkers of oxidative stress showed patterns similar to that of blood glucose, and the histopathological
examination of the pancreas mainly indicated focal area of a necrotic islet and multifocal area of mild
infiltration in both groups.
Conclusion: The data obtained shows that alloxan at the investigated doses produced sustained hyper-
glycemia at 21st and 24th hour post administration, and 170 mg dosage of the compound is apparently
a better diabetogenic dose, particularly in terms of reduced animal mortality.
 2018 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Alloxan (5,5-dihydroxyl pyrimidine-2,4,6-trione) which is an
organic compound, a urea derivative is a carcinogen and cytotoxic
glucose analogue.1 It has the molecular formula, C4H2N2O4 and a
relative molecular mass (Mr) of 142.06 g/Mol. Alloxan is one of
the common diabetogenic agents used to assess the anti-diabetic
or hypoglycemic potential of both pure compounds and plant
extracts in studies involving diabetes.2 Compared to other diabeto-
genic compounds such as streptozotocin, dithizone, monosodium
glutamate, gold thioglucose and anti-insulin serum, it appears to
be the most used compound for the induction of diabetes in animal
experimental studies, probably because of its affordability and
availability.3Like other diabetogenic agents, alloxan causes diabetes by a
mechanism which basically involves partial degradation or
damage of the beta (b) cells of pancreatic islets, and subsequent
compromise in the quality and quantity of insulin produced by
these cells.4
The use of alloxan as a diabetogenic agent in experimental ani-
mals was first reported by Dunn Sheehan and McLetchie in their
study in which they successfully induced diabetes in experimental
rabbits.5
Several studies have thereafter reported the effective use of
alloxan for induction of diabetes in experimental animals,
particularly at a dosage of 150 mg per kg of body weight (single
intraperitoneal administration).6–9
However, in previous studies on diabetes in our laboratory, we
observed that single administration of alloxan at this dosage
(150 mg/kg BW) has a low success rate as most of the animals in
a study group do not attain a diabetic blood glucose level (Value
 200 mg/dL).10 This often leads to time, energy and animal loss,
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with alloxan in order to achieve the required number of diabetic
animals statistically relevant for the study. Increase of alloxan
dosage to 200 mg/kg BW appeared to be very effective as most of
the animals exhibited a blood glucose level greater than 200 mg/
dL. This however came with the problem of higher mortality rate.
Mortality from diabetes has been adduced to either initial hypo-
glycemic shock or emergence of diabetic complications or direct
kidney tubular cell toxicity.11 The placement of alloxan-treated
animals on 5–10% glucose solution in a bid to prevent hypo-
glycemic shock is often practiced but this intervention appears
not to be significantly helpful, and thus the problem of mortality
persists. High mortality rate is a major setback in diabetic studies.
First it increases the financial burden of the study as several ani-
mals, more than required have to be used in order to carry the
study to a meaningful and conclusive end. Secondly, it does not
allow for proper evaluation of the antidiabetic potential of the
investigated compound or test drug.
These challenges collectively necessitated the need to examine
the time course effects of alloxan using doses above 150 mg/kg BW
(170 and 200 mg/kg BW). It is expected that the information
obtained from this study will be helpful in suggesting the most
effective dose of alloxan for induction of diabetes in experimental
animals, vis-à-vis onset of experimental diabetes, period of stable
hyperglycemia and mortality rate. It will also assist researchers
with the precise time or period when stable diabetes is achieved
by the drug, and hence, the appropriate time to commence treat-
ments in diabetic studies involving alloxan. The latter will go a
long way in minimizing mortality in the experimental animals,
particularly if the investigated extract or test compound is effec-
tive. This is because mortality occurrence and rate increase in the
diabetics when treatment is delayed; even when such treatments
have the potential to curtail or reverse diabetes and its associated
complications.2. Materials and methods
2.1. Chemicals
Alloxan monohydrate was obtained from Sigma Co St. Louis,
Missouri, USA.
2.2. Animal management and experimental design
Forty adult male Wistar rats (mean body weight of 124.39 g)
were purchased from the animal breeding unit of the Department
of Anatomy, University of Ibadan. The rats were randomized into
two groups (I and II, n = 20). All procedures for maintenance and
sacrifice (care and use) of animals were carried out according to
the criteria outlined by the National Academy of Science published
by the National Institute of Health12 and approved by the Ethical
Committee of the Faculty of Sciences, Lead City University. The ani-
mals were handled humanely, kept in plastic suspended cages,
placed in a well ventilated and hygienic rat house under suitable
conditions of temperature and humidity. They were provided rat
pellets, served water ad libitum and subjected to natural photope-
riod of 12 h light and 12 h dark cycle. The animals were allowed
two weeks of acclimatization prior to the commencement of the
study.
2.3. Alloxan preparation and administration
Fresh alloxan solution was prepared by dissolving an appropri-
ate amount of alloxan monohydrate (Sigma Chemical Co. USA) in
an appropriate volume of normal saline (0.9%). Groups I and IIanimals were administered 170 and 200 mg/kg BW single
intraperitoneal dose of alloxan respectively.
2.4. Monitoring of blood glucose concentration (BGC)
The accucheck active glucometer with disposable test strips
was used to determine blood glucose level in rats. Using aseptic
precautions, blood samples were collected through the tail of the
animals. The tail in each case was first wiped with surgical spirit
and then nibbed with a pair of sharp scissors. A Test Strip was fully
inserted into the glucometer before applying a drop of blood to
fully cover the test area inside the grey target. The principle of
the test is based on a glucose oxidase/peroxidase reaction, which
is specific for b-D-glucose. The test area of the strip is designed in
such a way that when a drop of blood is placed on the top surface,
color change occurs which is determined by the glucometer and
this is proportional to the concentration of glucose in the blood
sample. After collection of blood, the nibbled side of the tail was
rubbed with cotton wool soaked in surgical spirit to protect the
animal from infection and to arrest further bleeding. Blood glucose
levels were monitored at different time intervals consecutively.
First phase monitoring was done hourly for 3 h, second phase
was monitoring was at 3 h interval for 15 h, third phase at 6 h
interval for 12 h and last phase was monitored once after 9 h.
Two animals were taken from each group and sacrificed (by cer-
vical dislocation) at 6 h interval. The pancreas was harvested and
processed in each case for biochemical assays and histopathologi-
cal examination as described below.
2.5. Isolation and preparation of pancreas for biochemical analysis
The pancreas was rinsed with 1.15% KCl solution. Part of the
organ was prepared for histopathological examination by storing
in freshly prepared 10% (v/v) formalin solution and the remaining
was stored in ice-cold homogenizing buffer (Tris-HCl).
2.6. Histopathological examination of pancreas
The pancreas preserved in 10% formalin solution in each case
was first gross-examined for any observable lesion or tissue
derangement before it was processed using the automatic
tissue processor. The technique involved dehydrating the fixed tis-
sue placed in tissue baskets within their respective labels and pass-
ing through graded alcohol (70, 90, 95, and 100%). The tissues were
removed after dehydration and immersed in xylene solution to
clear the alcohol and facilitate molten wax impregnation. The tis-
sues were finally sectioned through rotary microtome (at 5m thick-
ness), stained with Haematoxylin and Eosin (H&E) and then
examined microscopically using standard techniques by Hulland.13
2.7. Homogenization of pancreas
Weighed part of the organ was mixed with 4 times volume Tris-
HCl (0.1 M, pH 7.4), the mixture was homogenized using Potter
Elvehjem type homogenizer. The homogenate was centrifuged at
5500 revolution per minute (rpm) for 20 min using cold Centrifuge
and the supernatant obtained was used to assay for lipid peroxida-
tion, protein concentration, superoxide dismutase (SOD), catalase
(CAT), and glutathione-s-transferase (GST) activities.
2.8. Biochemical assays
Protein concentration was estimated by the procedure of Lowry
et al.14 SOD activity was determined by the method of Misra and
Fridovich.15 The procedure described by Sinha was employed in
the estimation of catalase activity16 and GST activity was estimated























Fig. 2. Time course effect of Alloxan on Catalase (CAT) activity in the pancreas of
rat.
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Habig et al.17
2.9. Statistical analysis of data
Data analysis was performed using statistical software, Graph-
pad Prism, version 6.4. The statistical significance of difference
between groups was analyzed using the one-way analysis of vari-
ance (ANOVA) followed by independent-sample t test. The level of
significance was set at p < 0.05. The results are presented as the
mean ± SD.
3. Results
3.1. Blood glucose concentrations in rats administered 170 and 200
mg/kg/BW alloxan
Fig. 1 shows the effects of alloxan monohydrate at doses of 170
and 200 mg/kg BW on blood glucose level of rats. At the studied
doses, alloxan produced a multiphasic blood glucose response. Fol-
lowing its administration, significant alterations characterized by
inconsistent increase and decrease in blood glucose level (BGL)
was observed at different times of the study. However, right from
the first hour post alloxan injection, both groups of animals exhib-
ited diabetic glucose level (200 mg/dL), with lower dose of
alloxan (170 mg/kg BW) surprisingly producing higher blood glu-
cose level of 398.2 mg/dL compared to 231.2 mg/dL recorded in
animals treated with 200 mg/kg BW.
There was a drop in diabetic blood glucose level within the first
6 and 2 h in the animals injected with 170 and 200 mg/kg dosage
of the drug respectively. On the contrary, both doses at the 9th
and 12th h after administration respectively produced peak levels
of diabetic blood glucose (586.8 and 575.9 mg/dL). This phase was
succeeded by another sharp decline between the 15th and 21st h of
the study. This was followed by a very steep rise in blood glucose at
24 h in animals treated with 170 mg/kg dosage whereas this
increase was gradual in the animals administered 200 mg/kg
dosage until the 27th h when it became very steep. By the 36th
h. Animals treated with higher dose of alloxan (200 mg/kg/BW)
exhibited a higher level of diabetic glucose (581.3 mg/dL) com-
pared to those administered 170 mg/kg/BW (505.2 mg/dL).
3.2. Catalase activity in rats administered 170 mg/kg/BW and 200 mg/
kg/BW alloxan
Fig. 2 depicts the effects of alloxan monohydrate on pancreatic

























Fig. 1. Time course effect of Alloxan on blood glucose level of rat.200 mg/kg BW) of alloxan caused an initial decrease in CAT activity
up to the 6th h after administration. This was followed by a sudden
increase at the 9th h and till the 12th h in 170 and 200 mg/kg BW
groups respectively. The observed increase was steeper in the for-
mer. By the 12th h, Animals treated with the lower dosage (170
mg/kg BW) exhibited a sharp drop in CAT activity whereas those
treated with higher dosage (200 mg/kg BW) showed the same level
of decline by the 15th h of the study. The highest level of CAT activ-
ity was observed in both groups of animals at the 27th h of the
study.
3.3. Superoxide dismutase activity in rats administered 170 mg/kg/BW
and 200 mg/kg/BW alloxan
The effects of alloxan monohydrate on superoxide dismutase
(SOD) activity in the pancreas of rats at the administered doses
(170 and 200 mg/kg BW) are summarized in Fig. 3. In the group
of animals treated with 170 mg/kg BW, a slight increase in SOD
activity was observed between 3 and 6 h after alloxan
administration.
This activity was maintained till the 9th h, followed by a
decrease in the activity at 12th h and this level of activity was
maintained till the end of the experiment (27th h). In the 200
mg/kg BW treated group of animals, SOD activity in the pancreas
was slightly and gradually increased up to the 12th h after alloxan
administration. Thereafter, a decrease in SOD activity was noted at
the 15th h of the study, and this was followed by another phase of






















Fig. 3. Time course effect of Alloxan on Superoxide dismutase (SOD) activity in the
pancreas of rat.
Fig. 4. Time course effect of Alloxan on Malondialdehyde (MDA) level in the
pancreas of rat.
























Fig. 5. Time course effect of Alloxan on Glutathione –S-transferase (GST) activity in
the pancreas of rat.
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and 200 mg/kg/BW alloxan
The effects of alloxan monohydrate on the physiological level of
Malondialdehyde (MDA) of rats at the administered doses (170 and
200 mg/kg BW) are represented by Fig. 4. The effects did not follow
any uniform or specific pattern of increase or decrease. Rather, at
both doses, the diabetogenic compound caused an inconsistent
increase and decrease in pancreatic MDA concentration with time.
At a lower dose (170 mg/kg BW), alloxan administration caused
gradual increase in the level of MDA in experimental rat up to 9
h and a sudden drastic upsurge, reaching a peak MDA level at 12
h. This was immediately followed by a steep decrease by 15 h
and finally another gradual increase in the concentration of MDA
was observed up to the 27 h. At higher dose of 200 mg/kg BW,
the drug had similar effect on MDA up to 6 h showing a gradual
increase in Malondialdehyde concentration but producing higher
amount of MDA. This was followed by a decline till 12 h with high-
est level of Malondialdehyde reached at 15 h, then a sharp decline
up to 27 h.Fig. 6. Plates show focal area of a necrotic islet (orange arrow) and multifocal area
of mild infiltration by inflammatory cells (black arrows), intralobular and interlob-
ular ducts are essentially normal and in some cases contain pancreatic secretion
(slender arrow) and normal exocrine acini (dotted arrows). A = 170 mg/kg BW
alloxan treated rat, B = 200 mg/kg BW alloxan treated rat. 6 h, 12 h, 18 h and 24 h3.5. Glutathione-S-transferase (GST) activity in rats administered 170
and 200 mg/kg/BW alloxan
Fig. 5 shows the effects of alloxan monohydrate on Glutathione-
S-transferase (GST) activity in the pancreas of experimental rats.
Alloxan showed similar effects on pancreatic GST activity at the
investigated doses of 170 and 200 mg/kg BW. Post alloxan injec-
tion, GST activity initially decreased up to 6 and 9 h respectively
in groups of animals administered 170 and 200 mg/kg dosage of
the drug. This was followed by increased GST activity phase in both
groups. The period of increased activity was brief in the 200 mg/kg
BW treated group, notable at the 9th h and for a longer period in
the 170 mg/kg BW treated counterparts, notable from the 12th to
the 15th h of the study. This phase of increased GST activity was
subsequently ended by decline in GST activity in both groups.represent post alloxan treatment time.3.6. Photomicrographs of thin sections (5 mm) of pancreas of rats
treated with 170 and 200 mg/kg BW alloxan; harvested at different
time interval and stained with H &E (400)
The effects of alloxan on the histology of the pancreas of rats
treated with 170 and 200 mg/kg BW of the diabetogenic drug for
different period of time are represented by Fig. 6. The resultsobtained generally showed mild disseminated congestion, focal
area of a necrotic islet and multifocal area of mild infiltration by
inflammatory cells along with normal exocrine acini, intralobular
and interlobular ducts which in some cases contain pancreatic
secretion. Nonetheless, the histopathological changes in the pan-
creas appeared not to have varied with time in both groups.
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Lack of curative drugs for diabetes supports the need for contin-
uous research on the disease and its related aspects, and the use of
experimental animals for such purpose greatly extricate the risks
humans are exposed to in clinical studies. In a bid to understanding
the pathophysiology of diabetes and ultimately find a ‘perfect drug
antidote‘ for the condition, alloxan is widely used for induction of
diabetic hyperglycemia in different animal models.18 However, its
use at a common dosage of 150 mg/kg BW has a couple of limita-
tions, particularly in terms of animal mortality, low percentage
induction and instability of the hyperglycemia induced. The pre-
sent study examined the time course effects of alloxan with a view
to suggesting the probable effective dose of the compound for ani-
mal studies.
The doses of alloxan (170 and 200 mg/kg BW) examined in this
study produced a multiphasic blood glucose response character-
ized by marked fluctuations in concentration. This observation is
consistent with the previous reports on the use of alloxan for
induction of experimental diabetes.1,10,11,19 The inconsistent
increase and decrease in blood glucose level (BGL) observed in rats
at different times in this study may reflects the anomaly of alloxan
as a diabetogenic drug as proposed by Jain and Arya.20 It could also
be due to interplay of time dependent physiological changes in fac-
tors such as number of functional beta cells, insulin concentration
and status of pancreatic antioxidant system, which are either
directly or indirectly capable of influencing the concentration of
blood glucose sequel to alloxan injection. This view is corroborated
by the claim of Szkudelski11 that the understanding of changes in
beta cells of the pancreas as well as in the whole organism after
alloxan or streptozotocin treatment is essential for using these
compounds as diabetogenic agents.
In the present study alloxan, both at 170 and 200 mg dosages
induced diabetic hyperglycemia (blood glucose  200 mg/dL or
11.1 mmol/L) in rats one hour post its administration. Previous
authors have also noted the immediate diabetogenicity of alloxan
following its administration to experimental animals. Lenzen1 in
his study titled ‘Alloxan and streptozotocin diabetes‘ informed that
notable hyperglycemia commenced in experimental rats one hour
after alloxan treatment (150 mg kg BW). Similar report ‘that
alloxan administration to rats causes immediate hyperglycemia
which reaches its peak within two or three hours was earlier com-
municated by Goldner and Gomori.21 According to Szkudelski,11
Alloxan is a hydrophilic and unstable substance with a half-life
of 1.5 min at neutral pH and 37 C. This implies that the time for
alloxan degradation (metabolism) is sufficiently short enough to
allow it to reach the pancreas very fast and in deleterious amount.
This possibly explains the one hour post alloxan diabetic effect
noted in this study.
Besides, alloxan toxicity in the pancreas is preceded by its rapid
uptake by the insulin-secreting beta cells and this has been pro-
posed to be one of the important features determining alloxan dia-
betogenicity.1,11 This occurs through cyclic reduction of alloxan,
leading to the production of reactive species, particularly hydroxy
radicals (OH⁄) which ultimately destroy the beta cells of the pan-
creas and consequently affects insulin production and
release.1,11,20 Inhibition of insulin secretion, a condition that may
invariably lead to hypoinsulinemia and hyperglycemia has been
linked with early post alloxan effect.1
Post alloxan effect was more evident in this study between the
9th and 12th h, as 170 and 200 mg/kg BW treated animals respec-
tively exhibited peak levels of hyperglycemia (586.8 and 575.9 mg/
dL) during this period (9 and 12 h post alloxan administration).
This was however followed by hypoglycemia which is characteris-
tic of experimental diabetes, between the 15th and 21st hour, and
at 36th hour, hyperglycemia was restored and apparently sus-tained in both groups. This observation agrees with the earlier
report of Goldner and Gomori,21 who hinted ‘that alloxan-
induced hyperglycemia in rats is followed by a severe and fatal
hypoglycemia, which after a duration of several hours yields to a
final hyperglycemia.
Arguably, the period of peak hyperglycemia noted in this study
(9th h for 170 mg/kg BW alloxan and 12th h for 200 mg/kg BW
alloxan) indicates maximal inhibition of insulin secretion and
action following optimal uptake of the compound by the secreting
granules of pancreatic beta cells. As postulated by Banerjee,22 sub-
sequent to uptake, alloxan induces the rupture of secretary granule
and cell membrane, leading to flooding of the circulation with
insulin, a phenomenon which accounts for severe hypoglycemia
as noted in this study. Nonetheless, the period of hyperglycemia
(15–21 h) in this study is at variance with that reported by Lenzen1
in which severe hypoglycemia was evident within 4–8 h in animals
administered 150 mg/kg BW alloxan. The time difference of hypo-
glycemia in the two studies may be due to the difference in dose of
alloxan or species of animals used.
Hypoglycemia in diabetes is a fatal phenomenon which usually
results in mortality.21 The mortality of animals recorded in this
study occurred during the period of severe hypoglycemia, with
170 and 200 mg/kg BW alloxan causing 5 and 10% mortality
respectively within 36 h. These values are quite low when com-
pared to previous report which associates 25, 33.3 and 40% mortal-
ity with 150, 160 and 170 mg/kg BW alloxan injection respectively
within 15 days.10 The different durations of the two studies is obvi-
ously responsible for the significant variation in degree of mortal-
ity observed.
As previously stated, reactive species play very important role
in the diabetogenicity of alloxan.1 In the presence of an intracellu-
lar thiol especially glutathione, alloxan undergoes a cyclic reaction
to generates reactive oxygen species such as superoxide radical
(O2⁄), and hydroxy radical (OH⁄) through the auto-oxidation of its
reduction product, dailuric acid. These radicals, particularly OH⁄
caused oxidative damage to the beta cells of the pancreas as evi-
dent by inflammation and necrosis of pancreatic islet cells in rats
injected with both 170 and 200 mg/kg BW alloxan in this study.
It was expected that the severity of histological damage in the pan-
creas should worsen with time. However, the histopathological
changes observed in the experimental animals appeared not to
have varied with time in both groups. This is probably as a result
of the short duration of alloxan exposure (27 h) in the animals.
Usually, superoxide radical (O2⁄) generated in tissues through
metabolism is catalytically converted to hydrogen peroxide
(H2O2) and molecular oxygen (O2) by superoxide dismutase
(SOD). H2O2 when accumulated is toxic to body tissues or cells.
Also, it is converted to deleterious OH⁄ in the presence of Fe2+
through Fenton reaction. In other to prevent this phenomenon,
catalase (another antioxidant enzyme) breaks down H2O2 into
water and oxygen, consequently curtailing free radical-induced
damage. In fact, catalase deficiency has been suggested to increase
the possibility of developing diabetes and related complications.23
Unfortunately, pancreas unlike other tissues such as liver and kid-
ney has very low contents of these antioxidant enzymes, making it
highly sensitive or susceptible to alloxan metabolism.24
In the present study, treatment of rats with alloxan at both 170
and 200 mg/kg BW caused marked changes (irregular increase and
decrease) in SOD and CAT activities as well as Malondialdehyde
(MDA) level in the pancreas. This may be a reflection of the normal
cellular antioxidant response/attempt to combat beta cell oxida-
tive damage or suppression of the antioxidant system, triggered
by alloxan administration. The changes in the activities of these
enzymes (SOD and CAT) and level of MDA noted in this study cor-
roborates the reports of previous studies on chemical - induced
diabetes.25,26 The decrease in catalase activity observed from 9 to
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catalase activity by increasing metabolic reactions, this postulation
supports the previous report on the expression of CAT in the pan-
creas of hyperglycemic rat by Suarsana et al.27 Malondialdehyde is
a metabolic index of lipid peroxidation. High level of Malondialde-
hyde observed around 9–15 h in both groups of animals depicts
increased level of free radicals produced in the pancreas of the ani-
mals. Beta cell damage by hyperglycemia-induced lipid peroxida-
tion has been suggested by Suarsana et al.27
5. Conclusion
In summary, comparing the diabetogenic effects of alloxan at
170 mg/kg BW and 200 mg/kg BW through intraperitoneal route
of administration did not show significant (P < 0.05) difference
between the two doses, particularly in respect to the stability of
the hyperglycemia induced. However, in terms of the severity of
induced hyperglycemia (diabetes) and low animal mortality rate,
the use of alloxan as a diabetogenic compound in animal studies
at a dosage of 170 mg/kg BW is apparently more effective.
Nonetheless, a longer duration of the study beyond 36 h is neces-
sary to ascertain the stability of the final phase of hyperglycemia
noticed in this study.
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